Avalide

Type: Product
Name: Avalide
First reported Aug 20 2014 - Updated Aug 20 2014 - 1 reports

Stock Update (NYSE:BMY): Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis® (apixaban) at the ESC Congress 2014

[Business Wire] – Bristol-Myers Squibb Company and Pfizer Inc. announced today that they will present 14 abstracts at the ESC Congress 2014, organized by the European Society of Cardiology, to be held August 30 to September 4 in Barcelona, Spain.Read ... [Published Jutia Group - Aug 20 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Milestone Pharmaceuticals Appoints Chief Medical Officer

By a News Reporter-Staff News Editor at Clinical Trials Week Milestone Pharmaceuticals Inc., a cardiovascular drug development company, announced the appointment of Francis Plat, MD, FAHA, as Chief Medical Officer of the Company. Dr. Plat is a board-certified ... [Published Pharmacy Choice - Aug 04 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 1 reports

Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Reports Second Quarter 2014 Financial Results

[Business Wire] – Bristol-Myers Squibb Company today reported financial results for the second quarter of 2014, which was highlighted by strong global sales for the company’s key brands; the achievement of important regulatory milestones for key brands ... [Published Jutia Group - Jul 24 2014]
First reported Jul 21 2014 - Updated Jul 21 2014 - 1 reports

Milestone Pharmaceuticals Appoints Chief Medical Officer

/PRNewswire/ - Milestone Pharmaceuticals Inc., acardiovascular drug development company, today announced theappointment of Francis Plat, MD, FAHA, as Chief Medical Officer of theCompany. Dr. Plat is a board-certified cardiologist with extensiveexperience ... [Published RCL Advisors - Jul 21 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Patent expiration, stagnant R&D spend seriously affect blockbuster sales of big pharma during 2007-2013

Patent expiration of several blockbusters and limited success in launching new molecules during the last few years are the two critical factors that  impacted the revenues of the top international pharmaceutical companies during the period 2007-2013. ... [Published PharmaBiz - Mar 28 2014]

Quotes

"I am highly enthused to join Milestone in its development of MSP-2017, a promising product candidate, to alleviate acute episodes of paroxysmal supraventricular tachycardia (PSVT)" said Dr. Plat
"MSP-2017 is a nasal self-administered treatment-in-the-pocket that"

More Content

All (8) | News (5) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (2) | Press Releases (0)
sort by: Date | Relevance
Stock Update (NYSE:BMY): Bristol-Myers Squibb a... [Published Jutia Group - Aug 20 2014]
Milestone Pharmaceuticals Appoints Chief Medica... [Published Pharmacy Choice - Aug 04 2014]
Bristol-Myers Squibb Company (NYSE:BMY) – Brist... [Published Jutia Group - Jul 24 2014]
Milestone Pharmaceuticals Appoints Chief Medica... [Published RCL Advisors - Jul 21 2014]
AVALIDE (Irbesartan And Hydrochlorothiazide) Ta... [Published DailyMed Drug Label Updates for the last seven ... - Jun 15 2014]
Patent expiration, stagnant R&D spend seriously... [Published PharmaBiz - Mar 28 2014]
Fact Sheet for Bristol Myers Squibb Co [Published Able2Act - Jan 02 2008]
Fact Sheet for Bristol Myers Squibb Co [Published Able2Act - Jan 02 2008]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
AVALIDE (Irbesartan And Hydrochlorothiazide) Ta... [Published DailyMed Drug Label Updates for the last seven ... - Jun 15 2014]
Updated Date: Jun 11, 2014 EST ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.